Clinical benefit with ripretinib as ≥4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study Meeting Abstract
| Authors: | Zalcberg, J. R.; Heinrich, M.; George, S.; Bauer, S.; Gelderblom, H.; Schöffski, P.; Serrano, C.; Jones, R. L.; Attia, S.; D'Amato, G.; Chi, P.; Reichardt, P.; Meade, J. N.; Reichert, V.; Shi, K.; Ruiz-Soto, R.; von Mehren, M.; Blay, J. Y. |
| Abstract Title: | Clinical benefit with ripretinib as ≥4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study |
| Meeting Title: | ESMO Virtual Congress 2020 |
| Journal Title: | Annals of Oncology |
| Volume: | 31 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2020 Sep 19-21/Oct 16-18 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2020-09-01 |
| Start Page: | S973 |
| End Page: | S974 |
| Language: | English |
| ACCESSION: | WOS:000573469102209 |
| DOI: | 10.1016/j.annonc.2020.08.1848 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1622MO -- Source: Wos |
